# Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

> **NCT02077881** · PHASE1,PHASE2 · COMPLETED · sponsor: **NewLink Genetics Corporation** · enrollment: 157 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Nab-Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Indoximod

## Key facts

- **NCT ID:** NCT02077881
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2018-01-17
- **Final completion:** 2018-10-17
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077881, "Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02077881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*